[New aspects of pharmaco-therapy for acute pancreatitis].
Despite improvement in intensive medical care management, the mortality rate from severe acute pancreatitis is still high. Attempt to reduce the mortality rate, some new drugs were investigated on experimental pancreatitis and clinical cases. There have been several clinical trials of somatostatin, somatostatin analogue octreotide, and a cholecystokinin A(CCK-A) receptor antagonist, loxiglumide, for the inhibition of pancreatic secretion. On the other hand, for the inhibition of the systemic inflammatory response, many studies in the use of the platelet-activating factor(PAF) antagonist, lexipafant, were reported in clinical trials. IS-741, a new synthetic anti-inflammatory agent, has been studied on various models of experimental pancreatitis. In this paper, it is introduced the results of these new drugs on experimental pancreatitis or clinical trials.